{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:42:53Z","timestamp":1790174573829,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1245\/s10434-018-6631-2","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T17:30:46Z","timestamp":1530811846000},"page":"3271-3279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study"],"prefix":"10.1245","volume":"25","author":[{"name":"on behalf of the RENAPE Network","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Malgras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Gayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Aoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9a","family":"Lo Dico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Eveno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Pautrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Delhorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Passot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Sgarbura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenael","family":"Ferron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Go\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,5]]},"reference":[{"key":"6631_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/10408440903044928","volume":"39","author":"B Price","year":"2009","unstructured":"Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009; 39:576\u2013588.","journal-title":"Crit Rev Toxicol"},{"key":"6631_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","volume":"20","author":"SH Moolgavkar","year":"2009","unstructured":"Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973\u20132005. Cancer Causes Control. 2009; 20:935\u2013944.","journal-title":"Cancer Causes Control"},{"key":"6631_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1179\/oeh.2007.13.4.398","volume":"13","author":"T Larson","year":"2007","unstructured":"Larson T, Melnikova N, Davis SI, et al. Incidence and descriptive epidemiology of mesothelioma in the United States, 1999\u20132002. Int J Occup Environ Health. 2007; 13:398-403.","journal-title":"Int J Occup Environ Health"},{"key":"6631_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","volume":"20","author":"M Deraco","year":"2013","unstructured":"Deraco M, Baratti D, Hutanu I, et al. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013; 20:1093\u20131100.","journal-title":"Ann Surg Oncol"},{"key":"6631_CR5","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1200\/JOP.2016.011908","volume":"12","author":"PH Sugarbaker","year":"2016","unstructured":"Sugarbaker PH, Turaga KK, Alexander HR, et al. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016; 12:928\u2013935.","journal-title":"J Oncol Pract"},{"key":"6631_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.suronc.2014.12.002","volume":"24","author":"J Hubert","year":"2015","unstructured":"Hubert J, Thiboutot E, Dub\u00e9 P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis. Surg Oncol. 2015; 24:41\u201346.","journal-title":"Surg Oncol"},{"key":"6631_CR7","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","volume":"49","author":"D Baratti","year":"2013","unstructured":"Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013; 49:3140\u20133148.","journal-title":"Eur J Cancer"},{"key":"6631_CR8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.47102\/annals-acadmedsg.V42N6p291","volume":"42","author":"GH Tan","year":"2013","unstructured":"Tan GH, Cheung M, Chanyaputhipong J, et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore. 2013; 42:291\u2013296.","journal-title":"Ann Acad Med Singapore"},{"key":"6631_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ctrv.2011.10.006","volume":"38","author":"P Mirarabshahii","year":"2012","unstructured":"Mirarabshahii P, Pillai K, Chua TC, et al. Diffuse malignant peritoneal mesothelioma\u2014an update on treatment. Cancer Treat Rev. 2012; 38:605\u2013612.","journal-title":"Cancer Treat Rev"},{"key":"6631_CR10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","volume":"21","author":"D Magge","year":"2014","unstructured":"Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014; 21:1159\u20131165.","journal-title":"Ann Surg Oncol"},{"key":"6631_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/jso.21177","volume":"99","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009; 99:109\u2013113.","journal-title":"J Surg Oncol"},{"key":"6631_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.amjsurg.2011.09.009","volume":"203","author":"B Goslin","year":"2012","unstructured":"Goslin B, Sevak S, Siripong A, et al. Outcomes of cytoreduction with hyperthermic intraperitoneal chemotherapy: our experience at a midwest community hospital. Am J Surg. 2012; 203:383\u2013386.","journal-title":"Am J Surg"},{"key":"6631_CR13","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S0399-8320(07)73964-7","volume":"31","author":"D Elias","year":"2007","unstructured":"Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007; 31:784\u2013788.","journal-title":"Gastroenterol Clin Biol"},{"key":"6631_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","volume":"65","author":"V Kepenekian","year":"2016","unstructured":"Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer. 2016; 65:69\u201379.","journal-title":"Eur J Cancer"},{"key":"6631_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00384-014-2029-1","volume":"30","author":"S Cao","year":"2015","unstructured":"Cao S, Jin S, Cao J, et al. Advances in malignant peritoneal mesothelioma. Int J Colorectal Dis. 2015; 30:1\u201310.","journal-title":"Int J Colorectal Dis"},{"key":"6631_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/030089160308900307","volume":"89","author":"YI Acherman","year":"2003","unstructured":"Acherman YI, Welch LS, Bromley CM, et al. Clinical presentation of peritoneal mesothelioma. Tumori. 2003; 89:269\u2013273.","journal-title":"Tumori"},{"key":"6631_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/sonc.2002.30236","volume":"29","author":"PH Sugarbaker","year":"2002","unstructured":"Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, et al. Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol. 2002; 29:51\u201361.","journal-title":"Semin Oncol"},{"key":"6631_CR18","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/cncr.25640","volume":"117","author":"TD Yan","year":"2011","unstructured":"Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011; 117:1855\u20131863.","journal-title":"Cancer"},{"key":"6631_CR19","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009; 27:6237\u20136242.","journal-title":"J Clin Oncol"},{"key":"6631_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","volume":"153","author":"HR Alexander","year":"2013","unstructured":"Alexander HR, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013; 153:779\u2013786.","journal-title":"Surgery"},{"key":"6631_CR21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/annonc\/mdl428","volume":"18","author":"TD Yan","year":"2007","unstructured":"Yan TD, Welch L, Black D, et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007; 18:827\u2013834.","journal-title":"Ann Oncol"},{"key":"6631_CR22","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","volume":"21","author":"AL Feldman","year":"2003","unstructured":"Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003; 21:4560\u20134567.","journal-title":"J Clin Oncol"},{"key":"6631_CR23","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1002\/cncr.21239","volume":"104","author":"D Nonaka","year":"2005","unstructured":"Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005; 104:2181\u20132188.","journal-title":"Cancer"},{"key":"6631_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1245\/s10434-006-9169-7","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Brun EA, Cerruto CA, et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007; 14:41\u201349.","journal-title":"Ann Surg Oncol"},{"key":"6631_CR25","doi-asserted-by":"publisher","first-page":"S553","DOI":"10.1245\/s10434-013-2976-8","volume":"20","author":"JC Leinwand","year":"2013","unstructured":"Leinwand JC, Zhao B, Guo X, et al. Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy. Ann Surg Oncol. 2013; 20:S553\u2013559.","journal-title":"Ann Surg Oncol"},{"key":"6631_CR26","first-page":"79","volume":"7","author":"HR Alexander","year":"2016","unstructured":"Alexander HR, Burke AP. Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol. 2016; 7:79\u201386.","journal-title":"J Gastrointest Oncol"},{"key":"6631_CR27","first-page":"29","volume":"7","author":"PH Sugarbaker","year":"2016","unstructured":"Sugarbaker PH, Van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol. 2016; 7:29\u201344.","journal-title":"J Gastrointest Oncol"},{"key":"6631_CR28","unstructured":"The National Cancer Institute\u2019s Common Terminology Criteria for Adverse Events v3.0update. Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronicapplications\/docs\/ctcaev3.pdf ."},{"key":"6631_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4251\/wjgo.v2.i1.31","volume":"2","author":"E Cotte","year":"2010","unstructured":"Cotte E, Passot G, Gilly FN, et al. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. 2010; 2:31\u201335.","journal-title":"World J Gastrointest Oncol"},{"key":"6631_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996; 82:359\u2013374.","journal-title":"Cancer Treat Res"},{"key":"6631_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221:29\u201342.","journal-title":"Ann Surg"},{"key":"6631_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","volume":"130","author":"LM Landrum","year":"2013","unstructured":"Landrum LM, Java J, Mathews CA, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013; 130:12\u201318.","journal-title":"Gynecol Oncol"},{"key":"6631_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2174\/157488711796575603","volume":"6","author":"S Shimada","year":"2011","unstructured":"Shimada S, Kuramoto M, Marutsuka T, et al. Adopting extensive intra-operative peritoneal lavage (EIPL) as the standard prophylactic strategy for peritoneal recurrence. Rev Recent Clin Trials. 2011; 6:266\u2013270.","journal-title":"Rev Recent Clin Trials"},{"key":"6631_CR34","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1245\/s10434-013-2874-0","volume":"20","author":"LE Harrison","year":"2013","unstructured":"Harrison LE, Tiesi G, Razavi R, et al. A phase I trial of thermal sensitization using induced oxidative stress in the context of HIPEC. Ann Surg Oncol. 2013; 20:1843\u20131850.","journal-title":"Ann Surg Oncol"},{"key":"6631_CR35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jtcvs.2014.10.041","volume":"149","author":"L Lang-Lazdunski","year":"2015","unstructured":"Lang-Lazdunski L, Bille A, Papa S, et al. Pleurectomy\/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg. 2015; 149:558\u2013565.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"6631_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009; 250:187\u2013196.","journal-title":"Ann Surg"},{"key":"6631_CR37","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015; 22:1686\u20131693.","journal-title":"Ann Surg Oncol"},{"key":"6631_CR38","first-page":"260","volume":"17","author":"JC Wagner","year":"1960","unstructured":"Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960; 17:260\u2013271.","journal-title":"Br J Ind Med"},{"key":"6631_CR39","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1200\/JCO.2007.15.2868","volume":"26","author":"GR Simon","year":"2008","unstructured":"Simon GR, Verschraegen CF, J\u00e4nne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008; 26:3567\u20133572.","journal-title":"J Clin Oncol"},{"key":"6631_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","volume":"7","author":"PA J\u00e4nne","year":"2005","unstructured":"J\u00e4nne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005; 7:40\u201346.","journal-title":"Clin Lung Cancer"},{"key":"6631_CR41","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21:2636\u20132644.","journal-title":"J Clin Oncol"},{"key":"6631_CR42","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","volume":"64","author":"G Carteni","year":"2009","unstructured":"Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma-results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009; 64:211\u2013218.","journal-title":"Lung Cancer"},{"key":"6631_CR43","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ejso.2006.03.009","volume":"32","author":"R Garcia-Carbonero","year":"2006","unstructured":"Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006; 32:676\u2013681.","journal-title":"Eur J Surg Oncol"},{"key":"6631_CR44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jtcvs.2012.10.042","volume":"145","author":"RB Cameron","year":"2013","unstructured":"Cameron RB, Hou D. Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation. J Thorac Cardiovasc Surg. 2013; 145:496\u2013504.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"6631_CR45","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1081\/CNV-120023766","volume":"21","author":"DT Le","year":"2003","unstructured":"Le DT, Deavers M, Hunt K, et al. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest. 2003; 21:682\u2013689.","journal-title":"Cancer Invest"},{"key":"6631_CR46","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","volume":"43","author":"PH Sugarbaker","year":"2017","unstructured":"Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017; 43:1228\u20131235.","journal-title":"Eur J Surg Oncol"},{"key":"6631_CR47","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","volume":"254","author":"F Quenet","year":"2011","unstructured":"Quenet F, Goere D, Mehta SS et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011; 254:294\u2013301.","journal-title":"Ann Surg"},{"key":"6631_CR48","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1245\/s10434-010-1080-6","volume":"17","author":"AU Blackham","year":"2010","unstructured":"Blackham AU, Shen P, Stewart JH, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010; 17:2720\u20132727.","journal-title":"Ann Surg Oncol"},{"key":"6631_CR49","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","volume":"9","author":"M Hazarika","year":"2004","unstructured":"Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (Alimta). The Oncologist. 2004; 9:482\u2013488.","journal-title":"The Oncologist"},{"key":"6631_CR50","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.suronc.2016.05.014","volume":"25","author":"D Badrudin","year":"2016","unstructured":"Badrudin D, Perrault-Mercier C, Bouchard-Fortier A, et al. Pharmacokinetics and the effect of heat on intraperitoneal pemetrexed using a murine model. Surg Oncol. 2016; 25:435\u2013440.","journal-title":"Surg Oncol"},{"key":"6631_CR51","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1053\/ejso.2000.0983","volume":"26","author":"SR Pestieau","year":"2000","unstructured":"Pestieau SR, Stuart OA, Sugarbaker PH. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. Eur J Surg Oncol. 2000; 26:696\u2013700.","journal-title":"Eur J Surg Oncol"},{"key":"6631_CR52","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1097\/IGC.0b013e3182a616a7","volume":"23","author":"S Gouy","year":"2013","unstructured":"Gouy S, Belghiti J, Uzan C, et al. Accuracy and reproducibility of the peritoneal cancer index in advanced ovarian cancer during laparoscopy and laparotomy. Int J Gynecol Cancer. 2013; 23:1699\u20131703.","journal-title":"Int J Gynecol Cancer"},{"key":"6631_CR53","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5858\/133.8.1317","volume":"133","author":"AN Husain","year":"2009","unstructured":"Husain AN, Colby TV, Ord\u00f3\u00f1ez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009; 133:1317\u20131331.","journal-title":"Arch Pathol Lab Med"},{"key":"6631_CR54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010; 28:63\u201368.","journal-title":"J Clin Oncol"},{"key":"6631_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/jso.21068","volume":"98","author":"AG Portilla","year":"2008","unstructured":"Portilla AG, Shigeki K, Dario B, et al. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008; 98:228\u2013231.","journal-title":"J Surg Oncol"},{"key":"6631_CR56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ejso.2012.01.001","volume":"38","author":"D Elias","year":"2012","unstructured":"Elias D, Souadka A, Fayard F, et al. Variation in the peritoneal cancer index scores between surgeons and according to when they are determined (before or after cytoreductive surgery). Eur J Surg Oncol. 2012; 38:503\u2013508.","journal-title":"Eur J Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-018-6631-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6631-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6631-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T15:07:05Z","timestamp":1693753625000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-018-6631-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,5]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["6631"],"URL":"https:\/\/doi.org\/10.1245\/s10434-018-6631-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,5]]},"assertion":[{"value":"28 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None declared.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}